These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

261 related items for PubMed ID: 2821890

  • 1. Clinical isolate of herpes simplex virus type 2 that induces a thymidine kinase with altered substrate specificity.
    Ellis MN, Keller PM, Fyfe JA, Martin JL, Rooney JF, Straus SE, Lehrman SN, Barry DW.
    Antimicrob Agents Chemother; 1987 Jul; 31(7):1117-25. PubMed ID: 2821890
    [Abstract] [Full Text] [Related]

  • 2. Drug resistance patterns of herpes simplex virus isolates from patients treated with acyclovir.
    McLaren C, Chen MS, Ghazzouli I, Saral R, Burns WH.
    Antimicrob Agents Chemother; 1985 Dec; 28(6):740-4. PubMed ID: 3002245
    [Abstract] [Full Text] [Related]

  • 3. An acyclovir-resistant strain of herpes simplex virus type 2 which is highly virulent for mice.
    Sakuma S, Yamamoto M, Kumano Y, Mori R.
    Arch Virol; 1988 Dec; 101(3-4):169-82. PubMed ID: 2845890
    [Abstract] [Full Text] [Related]

  • 4. Altered thymidine-thymidylate kinases from strains of herpes simplex virus with modified drug sensitivities to acyclovir and (E)-5-(2-bromovinyl)-2'-deoxyuridine.
    Fyfe JA, McKee SA, Keller PM.
    Mol Pharmacol; 1983 Sep; 24(2):316-23. PubMed ID: 6310366
    [Abstract] [Full Text] [Related]

  • 5. Low levels of herpes simplex virus thymidine- thymidylate kinase are not limiting for sensitivity to certain antiviral drugs or for latency in a mouse model.
    Coen DM, Irmiere AF, Jacobson JG, Kerns KM.
    Virology; 1989 Feb; 168(2):221-31. PubMed ID: 2536980
    [Abstract] [Full Text] [Related]

  • 6. Biological and biochemical characterization of clinical isolates of herpes simplex virus type 2 resistant to acyclovir.
    Oliver NM, Collins P, Van der Meer J, Van't Wout JW.
    Antimicrob Agents Chemother; 1989 May; 33(5):635-40. PubMed ID: 2546486
    [Abstract] [Full Text] [Related]

  • 7. Altered substrate specificity of herpes simplex virus thymidine kinase confers acyclovir-resistance.
    Darby G, Field HJ, Salisbury SA.
    Nature; 1981 Jan 01; 289(5793):81-3. PubMed ID: 6256650
    [Abstract] [Full Text] [Related]

  • 8. Selection and characterisation of acyclovir-resistant herpes simplex virus type 1 mutants inducing altered DNA polymerase activities.
    Larder BA, Darby G.
    Virology; 1985 Oct 30; 146(2):262-71. PubMed ID: 2996220
    [Abstract] [Full Text] [Related]

  • 9. Inactivators of herpes simplex virus ribonucleotide reductase: hematological profiles and in vivo potentiation of the antiviral activity of acyclovir.
    Spector T, Lobe DC, Ellis MN, Blumenkopf TA, Szczech GM.
    Antimicrob Agents Chemother; 1992 May 30; 36(5):934-7. PubMed ID: 1324641
    [Abstract] [Full Text] [Related]

  • 10. Sensitivity monitoring of clinical isolates of herpes simplex virus to acyclovir.
    Collins P, Ellis MN.
    J Med Virol; 1993 May 30; Suppl 1():58-66. PubMed ID: 8245894
    [Abstract] [Full Text] [Related]

  • 11. Superior cytotoxicity with ganciclovir compared with acyclovir and 1-beta-D-arabinofuranosylthymine in herpes simplex virus-thymidine kinase-expressing cells: a novel paradigm for cell killing.
    Rubsam LZ, Davidson BL, Shewach DS.
    Cancer Res; 1998 Sep 01; 58(17):3873-82. PubMed ID: 9731497
    [Abstract] [Full Text] [Related]

  • 12. Characterization of latent infections in mice inoculated with herpes simplex virus which is clinically resistant to acyclovir.
    Field HJ, Lay E.
    Antiviral Res; 1984 Apr 01; 4(1-2):43-52. PubMed ID: 6331304
    [Abstract] [Full Text] [Related]

  • 13. Alterations in substrate specificity and physicochemical properties of deoxythymidine kinase of a drug-resistant herpes simplex virus type 1 mutant.
    Veerisetty V, Gentry GA.
    J Virol; 1983 Jun 01; 46(3):901-8. PubMed ID: 6304349
    [Abstract] [Full Text] [Related]

  • 14. Deoxythymidine kinase induced in the HELA TK- cells by herpes simplex virus type I and type II. Substrate specificity and kinetic behavior.
    Cheng YC.
    Biochim Biophys Acta; 1976 Dec 08; 452(2):370-81. PubMed ID: 188465
    [Abstract] [Full Text] [Related]

  • 15. Effects of acyclovir, oxetanocin-G, and carbocyclic oxetanocin-G in combinations on the replications of herpes simplex virus type 1 and type 2 in Vero cells.
    Saijo M, Suzutani T, Yoshida I.
    Tohoku J Exp Med; 1992 May 08; 167(1):57-68. PubMed ID: 1333651
    [Abstract] [Full Text] [Related]

  • 16. Thymidine kinase with altered substrate specificity of acyclovir resistant varicella-zoster virus.
    Shiraki K, Ogino T, Yamanishi K, Takahashi M.
    Biken J; 1986 Mar 08; 29(1):7-10. PubMed ID: 3022711
    [Abstract] [Full Text] [Related]

  • 17. Mutant varicella-zoster virus thymidine kinase: correlation of clinical resistance and enzyme impairment.
    Roberts GB, Fyfe JA, Gaillard RK, Short SA.
    J Virol; 1991 Dec 08; 65(12):6407-13. PubMed ID: 1658351
    [Abstract] [Full Text] [Related]

  • 18. Molecular analysis of a neurovirulent herpes simplex virus type 2 strain with reduced thymidine kinase activity.
    Tanaka S, Toh Y, Mori R.
    Arch Virol; 1993 Dec 08; 131(1-2):61-73. PubMed ID: 8392322
    [Abstract] [Full Text] [Related]

  • 19. Intracellular uptake of thymidine and antiherpetic drugs for thymidine kinase-deficient mutants of herpes simplex virus type 1.
    Bae PK, Kim JH, Kim HS, Chung IK, Paik SG, Lee CK.
    Antiviral Res; 2006 Jul 08; 70(3):93-104. PubMed ID: 16546268
    [Abstract] [Full Text] [Related]

  • 20. Characterization of acyclovir-resistant and -sensitive herpes simplex viruses isolated from a patient with an acquired immune deficiency.
    Schinazi RF, del Bene V, Scott RT, Dudley-Thorpe JB.
    J Antimicrob Chemother; 1986 Oct 08; 18 Suppl B():127-34. PubMed ID: 3025153
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.